HNF4A and diabetes mellitus: ,4HNF1A/HNF4A-MODY (HNF1A-MODY, MIM: 600495; HNF4A-MODY, MIM: 125850) are better treated with oral sulphonylureas whereas GCK-MODY (MIM: 125851) does not need treatment and is not at high risk of diabetes-related complications.2